Actionable news
0
All posts from Actionable news
Actionable news in IBB: iShares NASDAQ Biotechnology Index Fund,

Shire's long-acting ADHD drug wins U.S. approval

June 20 (Reuters) - The U.S. Food and Drug Administration (FDA) on Tuesday approved Shire Plc's long-acting therapy for attention deficit hyperactivity disorder (ADHD), adding another treatment to its stock of drugs for the cognitive condition that affects millions of children.

Shire's SHP465 drug, known as Mydayis, contains the same active ingredient as the company's widely used ADHD treatment Adderall XR but is formulated to last up to 16 hours. Dublin-based Shire's Adderall XR, which manages symptoms for up to 12 hours, is available in generic forms.

"It's obviously not a new molecule but it does extend delivery," said Dr. Gregory Mattingly, who has been a study investigator in multiple...


More